Review Article

Prognostic Role of the MicroRNA-200 Family in Various Carcinomas: A Systematic Review and Meta-Analysis

Table 1

Characteristics of the eligible studies evaluating high miRNA expression levels in tissue samples and patient survival data.

Study (year) (ref)CountryCancerStageTestCut-off valuemiRNASample sizeMFD Newcastle-Ottawa Quality Assessment Scale
SelectionCompatibilityOutcome

Feng et al. (2015) [13]ChinaHCCNAqRT-PCR/ISHROC200a115120 m★★★★
Li et al. (2015) [17]ChinaHCCI–IVqRT-PCR/ISHNA42916196 m★★★★★★★
Lu et al. (2015) [8]ChinaGCI–IVqRT-PCRMedian14114160 m★★★★★
Wang et al. (2015) [14]ChinaGliomaI–IVqRT-PCRNA200b1235 y★★★★★★★
Yao et al. (2015) [9]ChinaBCI–IIIqRT-PCRComparison w/normal group200b27810 y★★★★★★
Zhao et al. (2015) [18]ChinaNSCLC-qRT-PCRMedian200c7840 m★★★★★
Cao et al. (2014) [19]ChinaOCI–IVqRT-PCRMedian200a/b/c10056 m★★★★★★★
Diaz et al. (2014) [20]SpainCRCIIqRT-PCRMaxstat R package429127120 m★★★★★★★
Kim et al. (2014) [21]KoreaNSCLCI–IVqRT-PCRMedian200c72125 m★★★★★★★★
Li et al. (2014) [22]ChinaNSCLCIIIB-IVqRT-PCRMinimum P value200c15018.5 [9.6] m★★★★★★★★
Liu et al. (2014) [23]ChinaHCCI–IVISHMedian141212100 m★★★★★
Song et al. (2014) [24]ChinaGCI–IVqRT-PCRMedian/Lowest quintile values200a/b/c373112 m★★★★★
Tejero et al. (2014) [25]SpainNSCLCI–IIIqRT-PCRMaxstat R package141/200c155160 m★★★★★★★★
Zhang et al. (2014) [26]ChinaASTIII-IVqRT-PCRMedian200b122120 m★★★★★★★★★
Zhu et al. (2014) [11]ChinaPCI–IVqRT-PCRMean14194200 m★★★★★★
Zhu et al. (2014) [15]ChinaNSCLCI–IVqRT-PCRROC4297030 m★★★★
Berghmans et al. (2013) [16]EuropeNSCLCIV (79%)qRT-PCRpredicted score200c3860 m★★★★★★★
Huang et al. (2013) [27]ChinaHCCI-IIqRT-PCRMean429138140 m★★★★★★
Li et al. (2013) [28]ChinaCRCI–IIIqRT-PCRMedian42910782 m★★★★★★★
Tang et al. (2013) [29]ChinaGCI–IVISHMedian200b/c126NA★★★★★
Torres et al. (2013) [10]EuropeEECI–IVqRT-PCRMedian/ROC200c/429 [429]30150 m★★★★★★
Xiao et al. (2013) [30]ChinaHCCI–IIIqRT-PCRMean200a12060 m★★★★★★
Zhao at al. (2013) [12]ChinaPCI–IVqRT-PCRMedian1414050 m★★★★
Leskelä et al. (2011) [31]SpainOCI–IVqRT-PCRMedian429 [141, 200a/b/c, 429]72128 m★★★★
Marchini et al. (2011) [32]ItalyOCIqRT-PCRContal & O’Quigley method200b/c (A)89240 m★★★★
200c (B)55
Yu et al. (2010) [33]JapanPCI–IVqRT-PCRMedian200c99101 m★★★★★★

[Value] indicates the microRNA type or maximum follow-up duration for progression-free survival.
MFD: maximal follow-up duration, AST: astrocytoma, BC: breast cancer, CRC: colorectal cancer, EEC: endometrioid endometrial carcinoma, EOC: epithelial ovarian cancer, ESC: esophageal squamous cancer, GC: gastric cancer, HCC: hepatocellular carcinoma, OC: ovarian cancer, PC: pancreatic cancer, PrC: castration-resistant prostate cancer, NSCLC: non-small-cell lung cancer, ROC, receiver operating characteristic analysis, NA: not available, mo: months, wk: weeks, and y: years.
Study reporting both overall survival and progression-free survival data.
Study reporting only progression-free survival data.